U.S. markets closed

Fulgent Genetics, Inc. (FLGT)

NasdaqGM - NasdaqGM Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
21.70+0.01 (+0.05%)
Al cierre: 04:00PM EDT
21.65 -0.05 (-0.23%)
Fuera de horario: 06:47PM EDT

Fulgent Genetics, Inc.

4399 Santa Anita Avenue
El Monte, CA 91731
United States
626-350-0537
https://www.fulgentgenetics.com

Sector(es)Healthcare
IndustriaDiagnostics & Research
Empleados a tiempo completo1,184

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. Ming HsiehChairman & CEO1.66MN/D1956
Mr. Jian XieCOO & President755.73kN/D1966
Mr. Paul KimChief Financial Officer757.59kN/D1967
Dr. Hanlin Gao D.A.B.M.G., FACMG, M.D., Ph.D.Chief Scientific Officer & Laboratory Director630.61kN/D1967
Ms. Natalie PrescottGeneral Counsel & Chief Privacy OfficerN/DN/DN/D
Ms. Doreen NgVP of Operations & Compliance and GM of Houston OfficeN/DN/DN/D
Mr. Jakub SramVice President of Business Development & SalesN/DN/DN/D
Ms. Ellen TsuiVice President of Human ResourcesN/DN/DN/D
Mr. Brandon PerthuisChief Commercial OfficerN/DN/DN/D
Dr. Lawrence M. Weiss M.D.Chief Medical OfficerN/DN/D1957
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.

Gestión corporativa

La calificación ISS Governance QuickScore de Fulgent Genetics, Inc. a partir del 1 de marzo de 2024 es 5. Las puntuaciones principales son Auditoría: 2; Junta: 7; Derechos del accionista: 4; Compensación: 8.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.